Novartis puts patients first. We want to create value for all patients, including those who cannot afford treatments. In 2007, our access-to-medicines programs, valued at USD 937 million, reached 65.7 million patients globally. Through multilateral institutions and public-private partnerships, we provide free leprosy and tuberculosis treatment and our antimalarial drug Coartem® without profit to patients in the developing world.

We also offer discounts and support programs to patients in the developed world who lack medical insurance or cannot afford treatment. We designed one of the most far-reaching patient assistance programs ever implemented on a global scale for our cancer therapy Gleevec/Glivec®.

Value of medicines ›

We conduct health economic research to better understand the value of our medicines.

 

Drug pricing ›

Drug prices are under increased scrutiny as countries are faced with rising healthcare costs and limited budgets.

 

Patient safety ›

Once a medicine is on the market, we continue to assess risks or safety signals that may emerge.

 

Patient groups ›

Our commitment to high quality healthcare has led to an enduring partnership between Novartis and patient groups.